pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

592 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1602Endpoints1254BioSpace587Fierce Biotech583BioPharma Dive474raps199onclive165fda recalls104fda medwatch
therapy area
allOncology10822Rare Disease2804Immunology2566Cardiology2301Pulmonology1910Hematology1907Vaccines1658Psychiatry & CNS1111
  • Eli Lilly gives hospitals five days to submit 340B claims data or lose discount pricing
    Eli Lilly has issued a notice to more than 1,000 hospitals that take part in the federal 340B drug discount program, requiring them to provide comprehensive claims data within five days. The compa…
    STAT · 4mo agoRegulatoryNegative↗ source
  • ASCO meeting highlights grief alongside cancer data, honoring late oncologist Amy Lin
    At the annual American Society of Clinical Oncology meeting, scientists presented abundant new cancer data, but this year the program also gave space to the emotional side of oncology. Outgoing pr…
    STAT · 4mo agoNeutral↗ source
← prev
page 20 of 24
next →
95
globenewswire health73
fda press55
Ophthalmology882
Endocrinology & Metabolism699
Pain676
Nephrology675
  • FDA misses self-imposed deadline on electric shock device ban, prompting disability advocates' outcry
    The Food and Drug Administration did not issue a decision by the end of May as it had set for itself on whether to prohibit electrical shock devices used on people with intellectual disabilities an…
    STAT · 4mo agoRegulatoryNegative↗ source
  • Revolution Medicines' Daraxonrasib Doubles Survival in Pancreatic Cancer Trial, Study Shows
    Results from a late-stage trial of the experimental pill daraxonrasib were presented at the American Society of Clinical Oncology meeting. The data showed that patients receiving the drug lived alm…
    STAT · 4mo agoPositive readoutPositive↗ source
  • Summit Therapeutics' Akeso cuts death risk by 34% in Chinese lung cancer trial presented at ASCO 2026
    Summit Therapeutics reported at the ASCO 2026 meeting that its experimental drug Akeso lowered the risk of death by 34% for previously untreated lung cancer patients in China when compared with the…
    Endpoints · 4mo agoPositive readoutPositive↗ source
  • Ivonescimab cuts death risk by 34% in Chinese trial for squamous NSCLC
    Data presented at the American Society of Clinical Oncology showed that ivonescimab, a bispecific antibody combining two established cancer drugs, lowered the risk of death by 34% compared with sta…
    STAT · 4mo agoPositive readoutPositive↗ source
  • Phase 3 trial shows pre- and post-surgery hormone therapy improves outcomes for high-risk prostate cancer
    A phase 3 study called PROTEUS evaluated high‑risk, early‑stage prostate cancer patients who were scheduled for surgery. The trial compared a regimen that gave two hormone therapies before and afte…
    STAT · 4mo agoPositive readoutPositive↗ source
  • RevMed earns standing ovation at ASCO for pancreatic cancer data while Akeso faces caution
    At the American Society of Clinical Oncology meeting, RevMed captured audience attention with data on its pancreatic cancer therapy, earning a rare standing ovation. In contrast, presentations fro…
    STAT · 4mo agoNeutral↗ source
  • Ultra-low dose nivolumab shows survival benefit for head and neck cancer patients in India
    Researchers presented data at the American Society of Clinical Oncology meeting showing that an ultra‑low dose of the PD‑1 inhibitor nivolumab, given with chemotherapy, extended survival for patien…
    STAT · 4mo agoPositive readoutPositive↗ source
  • Ivonescimab cuts death risk by one-third in Chinese lung cancer trial, adds four-month survival
    A trial in China evaluated ivonescimab combined with chemotherapy in patients newly diagnosed with advanced non-small cell lung cancer. The study was presented at the American Society of Clinical O…
    BioPharma Dive · 4mo agoPositive readoutNeutral↗ source
  • BioNTech and Pfizer present bispecific cancer data at ASCO, FDA chief notes optimism
    At the American Society of Clinical Oncology meeting, BioNTech and Pfizer highlighted early results from bispecific antibody programs aimed at lung cancer. The companies described the data as promi…
    STAT · 4mo agoPositive readoutPositive↗ source
  • Merck touts promising ADC sacituzumab tirumotecan as potential cornerstone therapy at ASCO
    Merck highlighted a new antibody-drug conjugate, sacituzumab tirumotecan (sac-TMT), licensed from Chinese biotech Kelun-Biotech, at the ASCO meeting. The company said early clinical data have give…
    BioPharma Dive · 4mo agoPositive readoutPositive↗ source
  • Positive data from Bristol Myers in multiple myeloma and Pfizer in lung cancer unveiled at ASCO
    At the American Society of Clinical Oncology (ASCO) meeting, Bristol Myers Squibb presented early-stage results that showed a favorable response in a multiple myeloma trial. The data suggest the in…
    STAT · 4mo agoPositive readoutPositive↗ source
  • Replimune seeks third FDA approval attempt, Pfizer signs China deal, panel backs updated Covid vaccine
    Replimune is pursuing a third attempt to secure FDA approval for its investigational therapy, after two prior submissions did not succeed. Pfizer has entered into a new agreement to expand its pre…
    STAT · 4mo agoNeutral↗ source
  • Kenyan court halts U.S. plan for Ebola quarantine facility for Americans
    A Nairobi High Court on Friday ordered a stop to a U.S. proposal to build a quarantine center in Kenya for Americans who might have been exposed to a rare Ebola strain circulating in northeastern C…
    STAT · 4mo agoRegulatoryNegative↗ source
  • GC Therapeutics appoints former BlueRock executive Stefan Irion as chief scientific officer
    GC Therapeutics announced that Stefan Irion has joined the company as its new chief scientific officer. Irion previously served in the same capacity at BlueRock Therapeutics. Irion brings experien…
    STAT · 4mo agoNeutral↗ source
  • Acceleron veterans and Westlake back new IPF biotech Oorja Bio with $30 million Series A
    Entrepreneurs who previously brought the drug Winrevair to market have launched a new biotech, Oorja Bio, to target idiopathic pulmonary fibrosis, a hard-to-treat lung disease. The company announc…
    Endpoints · 5mo agoDealPositive↗ source
  • Full-Life Technologies secures $150M Series D financing
    Full-Life Technologies announced it has raised $150 million in a Series D financing round, comprising $110 million in the main tranche and an additional $40 million. The capital is intended to adv…
    Endpoints · 5mo agoDealNeutral↗ source
  • UK adopts tobacco-free generation law, mirroring Massachusetts policy
    The United Kingdom has passed a tobacco‑free generation law that bars retailers from selling cigarettes, vapes or nicotine pouches to anyone born on or after Jan. 1, 2009. Existing customers may co…
    STAT · 5mo agoRegulatoryPositive↗ source
  • Merck's China-sourced ADC shows survival benefit in Phase 3 endometrial cancer trial
    Merck & Co., in partnership with Chinese biotech Kelun-Biotech, reported that its experimental antibody-drug conjugate sacituzumab tirumotecan (Sac-TMT) met its primary endpoint in a global Phase 3…
    BioPharma Dive · 5mo agoPositive readoutPositive↗ source
  • Trump administration cuts childhood vaccine schedule, citing personal autonomy
    The opinion argues that the concept of patient autonomy does not apply to childhood vaccination because infants cannot refuse shots; the decision rests with parents. In January, the Department of…
    STAT · 5mo agoRegulatoryNegative↗ source
  • Regeneron immunotherapy combo comes up short in melanoma trial
    A two-drug regimen of Regeneron’s fianlimab and Libtayo didn’t significantly outperform Keytruda in a late-stage study, a finding that surprised Wall Street analysts and wiped out billions in marke…
    BioPharma Dive · 5mo agoRegulatoryNeutral↗ source
  • Basking Biosciences appoints former Pulmocide chief medical officer Lance Berman
    Basking Biosciences announced the addition of Lance Berman as its new chief medical officer. The appointment was highlighted in a recent industry column that tracks personnel changes. Berman comes…
    STAT · 5mo agoNeutral↗ source
  • Understanding MET Alterations in Non‑Small Cell Lung Cancer and Emerging Targeted Treatment Options
    The article outlines the primary MET alterations observed in non‑small cell lung cancer, focusing on gene amplification and exon 14 skipping mutations. It explains that these MET changes frequentl…
    onclive · 5mo agoNeutral↗ source
  • TROP2 scoring and MTAP loss emerge as key biomarkers for NSCLC treatment decisions
    Researchers are highlighting two molecular features-TROP2 expression and loss of the MTAP enzyme-as potential guides for therapy in non‑small cell lung cancer. Quantitative scoring of TROP2 by pat…
    onclive · 5mo agoNeutral↗ source